AOP Health’s Rapiblyk (landiolol) Receives the US FDA’s Approval for Atrial Fibrillation and Atrial Flutter in the Critical Care Setting
Shots:
- The US FDA has granted approval to Rapiblyk for treating severe heart condition supraventricular tachycardia (atrial fibrillation and atrial flutter) in critical care setting
- Approval was supported by 5 clinical trials assessing the safety & efficacy of Rapiblyk (9.3 to 74.6 mcg/kg/min) vs PBO in adults (n=317) with supraventricular tachycardia, showing 40-90% vs 0-11% reduction in the heart rate & 9.9% vs 1% AEs
- Rapiblyk, adrenergic receptor antagonist with beta 1/2 selectivity, lowers heart rate without affecting blood pressure. It is approved in the EU for treating supraventricular tachycardia, incl. atrial fibrillation & flutter, and managing non-compensatory sinus tachycardia
Ref: AOP Health | Image: AOP Health
Related News:- Applied Therapeutics Receives Complete Response Letter for Govorestat’s NDA for Treating Classic Galactosemia
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
